<DOC>
	<DOCNO>NCT02460575</DOCNO>
	<brief_summary>Phase I double blind randomize trial safety tolerability Lactobacillus reuteri DSM 17938 give five successive day healthy child . Sixty child receive study product treatment placebo ratio 2:1 follow 3 month safety outcome .</brief_summary>
	<brief_title>Safety Lactobacillus Reuteri Healthy Children Aged 2-24 Months</brief_title>
	<detailed_description>The study single center Phase 1 double blind placebo control trial Lactobacillus reuteri DSM 17938 child age 2-24 month . The study population base community register clinical trial center rural Peru protocol do highly control setting . The study intend enroll healthy child live resource constrain set chronic undernutrition diarrheal disease common , population likely receive benefit use probiotic product treatment acute infectious diarrhea environmental enteropathy . Up 100 subject enrol order obtain randomization 60 subject , receive study product placebo ratio 2:1 . Participants enrol age 8 week 24 month . There age stratification . Participants screen baseline history physical examination laboratory test determine HIV status child , well baseline laboratory test evaluate occult infection , hepatic function , renal function . Upon randomization subject screen randomized treatment arm . Product administer direct supervision study staff daily 5 day . The primary outcome safety tolerability product dose formulation . Safety assess monitor baseline laboratory test 5 28 day follow initiation therapy AE monitoring . Tolerability evaluate analyze 28 day diary card distribute randomized subject parent record child 's symptom ( specifically fever , anorexia/oral intake , vomit , diarrhea , irritability , rash , wheezing , open field allow describe issue child may experience grade severity ) . Secondary outcome include : 1 ) The assessment duration shed Lactobacillus reuteri ( Lr ) strain DSM 17938 follow administration . This determine endpoint PCR assay L. reuteri do stool collect D3 , D5 , D12 , D15 , D18 , D24 , D28 , D36 participant . The planned enrollment period four month participation individual subject 3 month . The study complete 7 month . Safety monitor treatment group , i.e. , infant assign active placebo study product conduct NIDDK appoint DSMB direction NIDDK Program Official .</detailed_description>
	<criteria>In order eligible participate study , subject must meet following criterion : Have parental permission form sign parent Be 8 week 24 month age preexist exclusion criterion Have parent willing comply plan study procedure available plan study visit 3 month . 1 ) No enrollment family member household follow present : 1 . Another study participant household 2 . Presence immune suppress individual use immunosuppressive agent ( include limited corticosteroid , methotrexate , etc . ) household member 3 . Presence serious congenital anomaly chronic medical condition opinion investigator would contraindicate participation household member , include history gastrointestinal surgery , chronic gastrointestinal illness , abnormal intestinal anatomy , abnormal bowel functionality The following risk factor level individual child : 2 ) Allergy penicillin , cephalosporin , clindamycin gentamicin 3 ) History antibiotic use last 30 day 4 ) Use probiotic product within past 30 day , include masato ( local product ferment bacteria ) yogurt product contain live bacterial culture . 5 ) History diarrheal illness within past 30 day ( See definition Protocol Appendix B ) 6 ) Presence fever preexist adverse event monitor study ( See Protocol Appendix B Definitions AEs specific adverse event monitor study ) 7 ) Positive result serum diagnostic test antibody HIV . 8 ) Presence severe anemia , define serum hemoglobin &lt; 7 gm/dL 9 ) Out range laboratory value total leucocyte count , BUN , Creatinine , AST , ALT , total bilirubin monitor potential adverse event , describe Appendix E. 10 ) Preenrollment stool sample ( collect within 14 day day 1 study ) positive L. reuteri PCR .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Safety</keyword>
</DOC>